The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
In 2024, Mercialys (Paris:MERY) achieved a solid performance, reflecting the realignment and improvement in the quality of its portfolio, as well as the successful diversification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback